Technology Portfolio

Galilaeus has developed production processes for the anthracycline group cytotoxic drugs, macrolide-based immunosuppressants and antibiotics. Our speciality is demanding, high-margin on-market APIs produced by fermentation processes.

We can arrange the manufacturing of these products to the Customer. Galilaeus has developed the technology and when entering to the commercial manufacturing, we make the document filing.

Product

CAS

Description

R&D

Upscaling

Tech Ready

Tacrolimus

104987-11-3

Immunosuppressant

 

 

X

Fusidic Acid /

Fusidate

6990-06-3 /

751-94-0

Antibiotic

 

 

X

Kanamycin

59-01-8

Antibiotic

 

X

 

Pentamycin

6834-98-6

Antibiotic

 

X

 

Amrubicin

110267-81-7

Cytotoxic

 

X

X

Daunorubicin

20830-81-3

Cytotoxic

 

 

X

BS-Doxorubicin*

25316-40-9

Cytotoxic

X

 

 

Idarubicin

57852-57-0

Cytotoxic

 

 

X

Zoledronic acid**

118072-93-8

Bisphosphonate

 

 

X

Acarbose

56180-94-0

Anti-diabetic drug

 

 

X

  * Biosynthetic Doxorubicin: fermentation process with no synthetic steps

  ** Synthetic production process

 

APIs already out-licensed on an exclusive basis are not shown in the list.

Galilaeus can perform development work and arrange manufacturing for other APIs, as well. We are open to your suggestions!

 

Contact us for more information